drugset / Trial / NCT04948788

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

NCT04948788

Phase 2 Unknown 102 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.

Timeline

Start
2021-10
Primary completion
2023-04
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject EDRALBRUTINIB Small molecule
Subject Gemcitabine Small molecule
Subject Linperlisib Small molecule
Subject Oxaliplatin Small molecule